Top Biotech and Pharma Stocks to Bet on Cancer Cure & Control

The technicals do not look good at all – with a decline lasting over the past two months. He would not touch this one at all. A 50 day moving average would be a buy signal if it can trade back above it.

Likes turnarounds, but it’s not ready. Want to see two things: 1) the stock hitting a 52-week high, and 2) the numbers moving in the right direction. Don’t do anything until then. Odds are this is going to zero.

Brazilian order? He owns warrants and his wife works as a consultant for them. They have orders for 500 units for a melanoma testing product. The delivery is subject to approval by authorities in Brazil. This could lead to hardware sales by June and revenues that begin to show up in Q4. The company thinks…

(A Top Pick Nov 03/20, Up 4.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with AMGN has triggered its stop at $228. To remain disciplined, we recommend covering the holding at this time.

(A Top Pick Dec 03/18, Up 47%) Celgene had made a number of mis-steps, including management applying for multiple FDA approvals. One thing he really liked about the acquisition was the price it was bought. The acquisition by BMY helped them diversify and it seems to be going well.

(A Top Pick Dec 23/21, Up 15.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with BMY has triggered its stop at $72. To remain disciplined, we recommend covering the position at this time. This will result in a net investment gain of 15%, when considering the previous recommendation to cover half the position.

It has always been part of their health care portfolio. It is losing some lustre and interest created by Covid but is still a good health care company with a good dividend. He likes others as well, maybe a bit better.

Good time to sell the stock. Has sold shares. Doesn't see positive upside for the stock. Numbers of the surface (dividend yield, cash flow yield) look good. Problem is that one of major drugs loses patent next year. Building pipeline of R&D in consumer drugs.

Healthcare is defensive because you have constant demand for these products and services. Investors should have exposure in this uncertain economy. Her pick here is JNJ, given its strong balance sheet. They offer pharmaceuticals, medical devices and consumer products, so are diversified. Aging demographics will fuel demand.

Made big money by selling off one division. Decent pipelines. Looking to sell off generic division. Dividend grows, share buybacks. Healthcare has become front and centre, and that's not going away. Safe haven. Underpriced at these levels. Yield is 3.55%. (Analysts’ price target is $88.96)

It has re-structured and is selling off some of its personal care business, thereby concentrating more on the pharmaceutical side. Not expensive and has a dividend yield over 6%.

Believes that company has undergone R & D overhaul. Strong pipeline of new products. One of the best growth stories in the sector. Expecting strong earnings going forward. Current share price is fair.

Likes healthcare. This pays a 4.5% dividend yield, because of the strength of their drugs. Likes their huge pipeline of drugs, spanning cell therapy, oncology and HIV. They just beat top and bottom lines and raised their 2022 guidance.

It trades at 13x earnings. Their pipeline is really good but was under pressure given drug pricing issues. This has outperformed the market this year. They have a strong pipeline of drugs and trades at an attractive valuation.

Their gene-editing biotechnology has lots of promise, but it's too early to tell, speculative. Buying this is a lottery ticket.

(A Top Pick Aug 29/14. Up 2.34%.) Radiation therapy equipment for treating cancer. Have been affected a little by foreign exchange rates. These are big ticket purchases, so she expects purchases have been delayed, but she has seen this come back. On the emerging-market side, it is a little bit more challenging. Still thinks the…

Has owned this since the mid-$80s. It offers the perfect blend of offence and defence perfectly. Investors have ignored this, but boasts a 20% a valuation discount to the S&P. You must be defensive, and Merck is a leader in healthcare.

Allan Tong’s Discover Picks You could then take that money and put it in Eli Lilly. There’s potential in LLY stock’s own Alzheimer’s drug. Also, the street is putting its hopes into LLY’s weight-loss drug, Mounjaro, when it starts selling in two or three years. After all, diabetes as at an all-time high in America.…

Allan Tong’s Discover Picks Abbott stocks trade at a 25.18x PE at a low 0.74 beta, and pays a 1.73% dividend. Its valuation is significantly lower than peers Stryker (36.4x) and Becton Dickinson (37.3x) while its profit margin scores much higher at 17.35% vs. 11.56% and 9.59% respectively. ROI is also comparably higher while Abbott…